# Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

> **NCT04435691** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 110 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **BIOLOGICAL:** Magrolimab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04435691
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-28
- **Primary completion:** 2025-03-25
- **Final completion:** 2025-03-25
- **Target enrollment:** 110 (ACTUAL)
- **Why stopped:** 75% \> Participants
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04435691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04435691, "Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04435691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*